Bristol-Myers Squibb And Celgene's Big Winner? Los Angeles Billionaire Patrick Soon-Shiong

  • 📰 Forbes
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 53%

Business Business Headlines News

Business Business Latest News,Business Business Headlines

Bristol-Myers Squibb's $74 billion acquisition of Celgene has one big winner: billionaire Patrick Soon-Shiong

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 394. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Bristol-Myers Squibb And Celgene's Big Winner? Los Angeles Billionaire Patrick Soon-ShiongPatrick Soon-Shiong’s net worth is up as Celgene shares surge following acquisition news.
Source: Forbes - 🏆 394. / 53 Read more »

Bristol-Myers Squibb looks to swallow CelgeneThe $90bn merger would be one of the biggest pharmaceutical deals in history Deals like these make generic production much more difficult, including for Revlimid. This is the result of letting pharma be dominated by MBAs instead of MDs.
Source: TheEconomist - 🏆 6. / 92 Read more »

Bristol-Myers Squibb to Acquire Celgene for About $74 BillionGlobal biopharmaceutical company Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction for about $74 billion. $74 billion ~ Piece of C🎂KE for Bristol-Myers Squibb bmsnews $5.6 billion ~ All🔥 hell 🔥breaks loose
Source: WSJ - 🏆 98. / 63 Read more »

Bristol-Myers Squibb's $74 billion acquisition of Celgene would combine two troubled companiesHeavy debt, faltering in 2018, and cracks in the deal: Bristol-Myers Squibb's $74 billion acquisition of Celgene combines 2 troubled companies. That's like merging Deutsche Bank and Commerzbank. Guess 1-(-1) = 2
Source: CNBC - 🏆 12. / 72 Read more »

Bristol-Myers Squibb buying Celgene in $74B dealBristol-Myers Squibb is spending $74 billion on fellow drugmaker Celgene in a deal aimed at stocking the combined company's development pipeline with cancer, immunology and cardiovascular treatments. Bristol would gain the cancer treatment Revlimid in the cash-and-stock deal announced...
Source: ABC - 🏆 471. / 51 Read more »

Here's why Bristol-Myers Squibb's record-breaking $74 billion biotech deal is facing investor backlashWall Street analysts questioned whether a combination would produce solutions to each of the two companies' problems.
Source: BusinessInsider - 🏆 729. / 51 Read more »